NCT00368472View on ClinicalTrials.gov

4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures

PHASE2CompletedINTERVENTIONAL
Enrollment

138

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

June 30, 2014

Study Completion Date

July 31, 2014

Conditions
Epilepsy
Interventions
DRUG

Perampanel

Perampanel 2 mg to 12 mg, once daily during the OLE study

Trial Locations (47)

2067

Chatswood

2650

Edegem

4558

Maroochydore

5011

Woodville

9000

Ghent

10617

Tallinn

11040

New Hyde Park

21287

Baltimore

30322

Atlanta

31520

Ramonville-Saint-Agne

32901

Melbourne

34205

Bradenton

34295

Montpellier

35294

Birmingham

37075

Göttingen

43210

Columbus

46009

Valencia

59037

Lille

72205

Little Rock

80218

Denver

80333

München

84088

West Jordan

85013

Phoenix

89081

Ulm

05401

Burlington

B-3000

Leuven

B-8700

Tielt

656 91

Brno

500 05

Hradec Králové

775 20

Olomouc

708 52

Ostrava

150 06

Prague

516 01

Rychnov nad Kněžnou

EE-51014

Tartu

FI-70210

Kuopio

FI-33520

Tampere

D-10365

Berlin

LV-1002

Riga

LT-50009

Kaunas

LT-50185

Kaunas

LT-92288

Klaipėda

LT-76231

Šiauliai

LT-03215

Vilnius

LT-08661

Vilnius

3012 KM

Rotterdam

112 45

Stockholm

DD1 9SY

Dundee

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT00368472 - 4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures | Biotech Hunter | Biotech Hunter